Researchers at Mass General Brigham built an AI model that estimates biological age and cancer survival from a face photograph.
Live Poll
Would you trust an AI scan of your face to tell you about your health?
October 23, 2026
Dana-Farber Study Links ctDNA to Prostate Cancer TreatmentResearchers identify ctDNA biomarkers that predict resistance to 177Lu-PSMA-617 therapy in prostate cancer patients.
October 20, 2026
Dana-Farber Review Finds Carboplatin Rationing ErrorsA study shows the Boston center's 2023 drug allocation policy frequently deviated from practice during a supply shortage.
October 20, 2026
Dana-Farber and Beth Israel Begin Cancer PartnershipThe two Boston institutions marked the start of their clinical collaboration with a ceremonial groundbreaking for a new hospital.
October 15, 2026
Dana-Farber to Transition Breast Oncology in BostonStarting October 19, breast oncology services will move to the Beth Israel Deaconess Medical Center partnership.
October 1, 2026
Aktis Oncology Started Phase 1b BActinium-2 TrialThe Boston-based company launched a new clinical trial for its radioconjugate therapy targeting B7-H3 expressing tumors.
September 23, 2026
ITM and Lumara Bio Will Present Cancer Study DataThe companies plan to share Phase 3 trial findings during the 2026 ASTRO meeting in Boston.
